Fidaxomicin: A novel macrolide antibiotic for Clostridium difficile infection

Consultant Pharmacist

Volumn 29, Issue 9, 2014, Pages 614-624

  Chahine, Elias B ^a   Sucher, Allana J ^b   Mantei, Karelee ^b  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

Clostridium difficile; Clostridium difficile inf ion; Clostridium difficile associated diarrhea; Fidaxomicin; Macrolide antibiotic

Indexed keywords

CYCLOSPORIN; FIDAXOMICIN; MACROLIDE; METRONIDAZOLE; PLACEBO; RIFAMYCIN; TACROLIMUS; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; NUCLEIC ACID SYNTHESIS INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTERICIDAL ACTIVITY; BIBLIOGRAPHIC DATABASE; CHEMICAL COMPOSITION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FECES; FEVER; FLATULENCE; FOOD; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; PAIN; PEPTOCLOSTRIDIUM DIFFICILE; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QT PROLONGATION; RECURRENT INFECTION; SEPSIS; SORE THROAT; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING; ADULT; DRUG EFFECTS; DRUG INTERACTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTESTINAL EXCRETION; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG INTERACTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INTESTINAL ELIMINATION; MACROLIDES; NUCLEIC ACID SYNTHESIS INHIBITORS; RECURRENCE; TISSUE DISTRIBUTION;

EID: 84937703930     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2014.614.     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available at http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=6. Accessed November 17, 2013.
2. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-98.
3. Cohen SH, Gerding DN, Johnson S et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
4. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35.
5. Loo VG, Bourgault AM, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703.
6. Freedberg D, Salmasian H, Friedman C et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:1794-801.
7. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
8. Johnson A. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Invest Drugs 2007;8:168-73.
9. DIFICID® (fidaxomicin) tablets [prescribing information]. San Diego, CA: Optimer Pharmaceuticals, Inc.; March 2013.
10. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Exp Opin Invest Drugs 2008;17:547-53.
11. Miller M. Fidaxomicin for the treatment of Clostridium difficile infection. Exp Opin Pharmacother 2010;11:1569-78.
12. Venugopal A, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012;54:568-74.
13. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012;55(S2):S127-31.
14. Finegold S, Molitoris D, Vaisanen M et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902.
15. Goldstein E, Babakhani F, Citron D. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012;55(S2):S143-8.
16. Karlowsky J, Laing N, Zhanel G. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52:4163-5.
17. Goldstein E, Citron D, Sears P et al. Comparative susceptibilities to FDX (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of FDX against Clostridium difficile infection. Antimicrob Agents Chemother 2011;55:5194-9.
18. Credito K, Appelbaum P. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4.
19. Biedenbach D, Ross J, Putnam S et al. In vitro activity of FDX (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 2010;54:2273-5.
20. Louie T, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012;55 (S2):S132-42.
21. Babakhani F, Gomez A, Robert N et al. Postantibiotic effect of FDX and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 2011;55:4427-9.
22. Babakhani F, Bouillaut L, Gomez A et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012;55(S2):S162-9.
23. Babakhani F, Bouillaut L, Sears P et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother 2013;68: 515-22.
24. Shue Y, Sears P, Shangle S et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52:1391-5.
25. Louie T, Miller M, Donskey C et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-8.
26. Louie TJ, Miller MA, Mullane KM et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
27. Cornely OA, Crook DW, Esposito R et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
28. Crook DW, Walker AS, Kean Y et al Study 003/004 Teams. Fidaxomicin versus vancomycin for Clostridium difficile infection: metaanalysis of pivotal randomized controlled trials. Clin Infect Dis 2012;55 Suppl 2:S93-103.
29. Mullane KM, Miller MA, Weiss K et al. Efficacy of FDX versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;53:440-7.
30. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: FDX versus vancomycin. Clin Infect Dis 2012;55 Suppl 2:S154-61.
31. Cornely OA, Miller MA, Fantin B et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with FDX or vancomycin. J Clin Oncol 2013;31:2493-9.
32. Clutter DS, Dubrovskaya Y, Merl MY et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2013;57:4501-5.
33. Shah H, Tallman AM, Capurso S. Clarifications about add-on payments for fidaxomicin. Am J Health Syst Pharm 2013;70:1015-6.
34. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating FDX versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304.
35. Bartsch SM, Umscheid CA, Fishman N et al. Is FDX worth the cost? An economic analysis. Clin Infect Dis 2013;57:555-61.
36. Stevens V, Onufrak N, Brown J. Fidaxomicin: balancing evidence and economics. Am J Health Syst Pharm 2012;69:931.
37. Debast SB, Bauer MP, Kuijper EJ; The Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2013;Oct 5. doi: 10.1111/1469-0691.12418. [Epub ahead of print]